Halozyme Therapeutics, Inc. (HALO) reported third-quarter 2024 adjusted earnings of $1.27 per share, which comprehensively beat the Zacks Consensus Estimate of 99 cents. The company had recorded adjusted earnings of 75 cents per share in the year-ago period.Total revenues in the third quarter increased 34% year over year to $290 million. Revenues surpassed the Zacks Consensus Estimate of $248 million.The top line was primarily driven by higher royalty payments from Roche (RHHBY) for Phesgo and J&J (JNJ) for ...